No Data
ORBUSNEICH: INTERIM REPORT 2024
Medical company Yiju Medical (06929.HK): Accelerating the flywheel, poised to unleash.
The journey of medical instrument industry to go global has always been a magnificent chapter that has inspired endless ideals and exploration desires. However, to navigate and win the trust and recognition of the international medical community, especially the overseas physician group, in the global technological wave, the difficulty is self-evident and can be described as a dual test of wisdom and strength. In the high-precision field of cardiovascular intervention therapy, Industry Chamber Medical has already emerged as a leader with extraordinary vision and strength. Based on the international market, its high-quality products have been sold to more than 70 countries and regions worldwide, and the contribution rate of overseas markets is even higher than 85%, making it a global leader in the field of cardiovascular.
Yiju Medical (06929) announced its interim results, with a shareholder's profit of US $18.828 million, down 25.2% year-on-year.
Yiju Medical (06929) released its six-month performance ending on June 30, 2024, with revenue of $78.91 million...
Express News | OrbusNeich Medical Group Holdings H1 Net Income USD 18.8 Million
Express News | OrbusNeich Medical Group Holdings H1 Gross Profit USD 55.8 Million
Express News | OrbusNeich Medical Group Holdings H1 Revenue USD 78.9 Million
Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 28%No Data
No Data
